TetraLogic Pharmaceuticals Corp. has entered into a licensing deal and research collaboration with an Australian research institute.
Financial terms of the deal with the Walter and Eliza Hall Institute of Medical Research were not disclosed.
The focus of the deal is TetraLogic’s experimental viral infection therapy birinapant, which in preclinical studies with rats conducted by the Hall Institute demonstrated effectiveness in combating the hepatitis B virus.
Read more at PBJ.com
